Interstitial injection of (32)P-chromic phosphate during lung cancer resection to treat occult lymphatic metastasis.
OBJECTIVE
We aimed to study the interstitial injection of (32)P-chromic phosphate colloids ((32)P-CP) during lung cancer resection to treat occult lymphatic metastasis, and to observe its medium-term and long-term effects.


METHODS
Seventy-three patients underwent surgery combined with injection of (32)P-CP with the dosage of 296-370 MBq/10 ml to the adipose and connective tissues neighboring pulmonary hilum, superior mediastinum, carina of trachea, and suspicious invaded pleura. Fifty-eight patients underwent only tumor resections served as control group. A monofactorial analysis by a chi test was conducted to determine the differences in positive rates of lymph nodes, the incidence of complications after the operation, the rate of supraclavicular lymph node metastasis, and the survival rate between the two groups. The survival curves were obtained using the Kaplan-Meier method and were compared by a log-rank test. The Cox's multivariate analysis was performed to identify the prognostic factors.


RESULTS
There was no significant difference between lymph node-positive rates and the incidences of major complications (P>0.05). The rate of supraclavicular lymph node metastasis in surgery plus (32)P-CP group was prominently lower than that in the control group (P<0.05). Three-year and 5-year survival rates of the two groups showed significant difference (P<0.05). A Kaplan-Meier analysis revealed prominent statistical differences between the two groups (P<0.05). The Cox's multivariate analysis showed that the injection of (32)P-CP is one of the independent predictors of survival rates.


CONCLUSIONS
Interstitial mediation with (32)P-CP during the resection of lung cancer is effective in inhibiting postoperative occult lymphatic metastasis, and showed satisfactory effects in improving patients' medium-term and long-term survival rates.
Gao
Wen
W
Nuclear Medicine Technology Institution of Southeast University, Nanjing, China.
Liu
Lu
L
Liu
Zhi-Yong
ZY
Li
Xu-Dong
XD
Li
Chen
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001830:Body Surface Area; D017608:Chromium Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*; D045604:Extracellular Fluid; D005260:Female; D006801:Humans; D007267:Injections; D007431:Intraoperative Complications; D008175:Lung Neoplasms / Q000473:pathology* / Q000601:surgery*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010710:Phosphates / Q000008:administration & dosage* / Q000627:therapeutic use*; D011829:Radiation Dosage; D015996:Survival Rate; D016896:Treatment Outcome
D017608:Chromium Compounds; D010710:Phosphates; C509370:chromic phosphate, 32P-labeled